1. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
N Engl J Med 2005;352:1305-1316.
2. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis.
N Engl J Med 2011;365:993-1003.
3. Leung TW, Wang L, Soo YO, Ip VH, Chan AY, Au LW, et al. Evolution of intracranial atherosclerotic disease under modern medical therapy.
Ann Neurol 2015;77:478-486.
4. Wong KS, Gao S, Chan YL, Hansberg T, Lam WW, Droste DW, et al. Mechanisms of acute cerebral infarctions in patients with middle cerebral artery stenosis: a diffusion-weighted imaging and microemboli monitoring study.
Ann Neurol 2002;52:74-81.
5. Ryoo S, Lee MJ, Cha J, Jeon P, Bang OY. Differential vascular pathophysiologic types of intracranial atherosclerotic stroke: a high-resolution wall magnetic resonance imaging study.
Stroke 2015;46:2815-2821.
6. Swartz RH, Bhuta SS, Farb RI, Agid R, Willinsky RA, Terbrugge KG, et al. Intracranial arterial wall imaging using high-resolution 3-tesla contrast-enhanced MRI.
Neurology 2009;72:627-634.
7. Bodle JD, Feldmann E, Swartz RH, Rumboldt Z, Brown T, Turan TN. High-resolution magnetic resonance imaging: an emerging tool for evaluating intracranial arterial disease.
Stroke 2013;44:287-292.
8. Alexander MD, Yuan C, Rutman A, Tirschwell DL, Palagallo G, Gandhi D, et al. High-resolution intracranial vessel wall imaging: imaging beyond the lumen.
J Neurol Neurosurg Psychiatry 2016;87:589-597.
9. Kim JS, Caplan LR. Non-atherosclerotic intracranial arterial diseases.
Front Neurol Neurosci 2016;40:179-203.
10. Biller J, Sacco RL, Albuquerque FC, Demaerschalk BM, Fayad P, Long PH, et al. Cervical arterial dissections and association with cervical manipulative therapy: a statement for healthcare professionals from the american heart association/american stroke association.
Stroke 2014;45:3155-3174.
11. Debette S, Compter A, Labeyrie MA, Uyttenboogaart M, Metso TM, Majersik JJ, et al. Epidemiology, pathophysiology, diagnosis, and management of intracranial artery dissection.
Lancet Neurol 2015;14:640-654.
12. Sato S, Toyoda K, Matsuoka H, Okatsu H, Kasuya J, Takada T, et al. Isolated anterior cerebral artery territory infarction: dissection as an etiological mechanism.
Cerebrovasc Dis 2010;29:170-177.
13. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries.
N Engl J Med 2001;344:898-906.
14. Kwon JY, Kim NY, Suh DC, Kang DW, Kwon SU, Kim JS. Intracranial and extracranial arterial dissection presenting with ischemic stroke: lesion location and stroke mechanism.
J Neurol Sci 2015;358:371-376.
15. Guillon B, Lévy C, Bousser MG. Internal carotid artery dissection: an update.
J Neurol Sci 1998;153:146-158.
17. Kim BM, Kim SH, Kim DI, Shin YS, Suh SH, Kim DJ, et al. Outcomes and prognostic factors of intracranial unruptured vertebrobasilar artery dissection.
Neurology 2011;76:1735-1741.
18. Krex D, König IR, Ziegler A, Schackert HK, Schackert G. Extended single nucleotide polymorphism and haplotype analysis of the elastin gene in Caucasians with intracranial aneurysms provides evidence for racially/ethnically based differences.
Cerebrovasc Dis 2004;18:104-110.
19. Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives.
Lancet Neurol 2008;7:1056-1066.
20. Takagi Y, Kikuta K, Nozaki K, Hashimoto N. Histological features of middle cerebral arteries from patients treated for moyamoya disease.
Neurol Med Chir (Tokyo) 2007;47:1-4.
21. Lin R, Xie Z, Zhang J, Xu H, Su H, Tan X, et al. Clinical and immunopathological features of moyamoya disease.
PLoS One 2012;7:e36386.
22. Takagi Y, Kikuta K, Nozaki K, Fujimoto M, Hayashi J, Imamura H, et al. Expression of hypoxia-inducing factor-1 alpha and endoglin in intimal hyperplasia of the middle cerebral artery of patients with moyamoya disease.
Neurosurgery 2007;60:338-345.
23. Kleinloog R, Regli L, Rinkel GJ, Klijn CJ. Regional differences in incidence and patient characteristics of moyamoya disease: a systematic review.
J Neurol Neurosurg Psychiatry 2012;83:531-536.
24. Liu W, Hitomi T, Kobayashi H, Harada KH, Koizumi A. Distribution of moyamoya disease susceptibility polymorphism p.R4810K in RNF213 in East and Southeast Asian populations.
Neurol Med Chir (Tokyo) 2012;52:299-303.
25. Starke RM, Crowley RW, Maltenfort M, Jabbour PM, Gonzalez LF, Tjoumakaris SI, et al. Moyamoya disorder in the United States.
Neurosurgery 2012;71:93-99.
26. Bang OY, Ryoo S, Kim SJ, Yoon CH, Cha J, Yeon JY, et al. Adult moyamoya disease: a burden of intracranial stenosis in East Asians?
PLoS One 2015;10:e0130663.
27. Chung JW, Kim SJ, Bang OY, Kim KH, Ki CS, Jeon P, et al. Determinants of basal collaterals in moyamoya disease: clinical and genetic factors.
Eur Neurol 2016;75:178-185.
29. Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease.
J Neurol Neurosurg Psychiatry 2008;79:900-904.
30. Kraemer M, Heienbrok W, Berlit P. Moyamoya disease in Europeans.
Stroke 2008;39:3193-3200.
31. Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes.
Ann Intern Med 2007;146:34-44.
32. Singhal AB, Topcuoglu MA, Fok JW, Kursun O, Nogueira RG, Frosch MP, et al. Reversible cerebral vasoconstriction syndromes and primary angiitis of the central nervous system: clinical, imaging, and angiographic comparison.
Ann Neurol 2016;79:882-894.
33. Hajj-Ali RA, Singhal AB, Benseler S, Molloy E, Calabrese LH. Primary angiitis of the CNS.
Lancet Neurol 2011;10:561-572.
34. Lee MJ, Cha J, Choi HA, Woo SY, Kim S, Wang SJ, et al. Blood-brain barrier breakdown in reversible cerebral vasoconstriction syndrome: implications for pathophysiology and diagnosis.
Ann Neurol 2017;81:454-466.
35. Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients.
Brain 2007;130(Pt 12):3091-3101.
37. Kaku Y, Morioka M, Ohmori Y, Kawano T, Kai Y, Fukuoka H, et al. Outer-diameter narrowing of the internal carotid and middle cerebral arteries in moyamoya disease detected on 3D constructive interference in steady-state MR image: is arterial constrictive remodeling a major pathogenesis?
Acta Neurochir (Wien) 2012;154:2151-2157.
38. Ryoo S, Cha J, Kim SJ, Choi JW, Ki CS, Kim KH, et al. Highresolution magnetic resonance wall imaging findings of moyamoya disease.
Stroke 2014;45:2457-2460.
39. Yuan M, Liu ZQ, Wang ZQ, Li B, Xu LJ, Xiao XL. High-resolution MR imaging of the arterial wall in moyamoya disease.
Neurosci Lett 2015;584:77-82.
40. Mossa-Basha M, Shibata DK, Hallam DK, de Havenon A, Hippe DS, Becker KJ, et al. Added value of vessel wall magnetic resonance imaging for differentiation of nonocclusive intracranial vasculopathies.
Stroke 2017;48:3026-3033.
42. Kuker W, Gaertner S, Nagele T, Dopfer C, Schoning M, Fiehler J, et al. Vessel wall contrast enhancement: a diagnostic sign of cerebral vasculitis.
Cerebrovasc Dis 2008;26:23-29.
43. van der Kolk AG, Zwanenburg JJ, Brundel M, Biessels GJ, Visser F, Luijten PR, et al. Intracranial vessel wall imaging at 7.0-T MRI.
Stroke 2011;42:2478-2484.
44. van der Kolk AG, Hendrikse J, Brundel M, Biessels GJ, Smit EJ, Visser F, et al. Multi-sequence whole-brain intracranial vessel wall imaging at 7.0 tesla.
Eur Radiol 2013;23:2996-3004.
45. Wright PJ, Mougin OE, Totman JJ, Peters AM, Brookes MJ, Coxon R, et al. Water proton T1 measurements in brain tissue at 7, 3, and 1.5 T using IR-EPI, IR-TSE, and MPRAGE: results and optimization.
MAGMA 2008;21:121-130.
46. Deng X, Zhang Z, Zhang Y, Zhang D, Wang R, Ye X, et al. Comparison of 7.0- and 3.0-T MRI and MRA in ischemictype moyamoya disease: preliminary experience.
J Neurosurg 2016;124:1716-1725.
47. Harteveld AA, Denswil NP, Siero JC, Zwanenburg JJ, Vink A, Pouran B, et al. Quantitative intracranial atherosclerotic plaque characterization at 7T MRI: an ex vivo study with histologic validation.
AJNR Am J Neuroradiol 2016;37:802-810.
48. Sanidas E, Dangas G. Evolution of intravascular assessment of coronary anatomy and physiology: from ultrasound imaging to optical and flow assessment.
Eur J Clin Invest 2013;43:996-1008.
49. Pavlin-Premrl D, Sharma R, Campbell BCV, Mocco J, Opie NL, Oxley TJ. Advanced imaging of intracranial atherosclerosis: lessons from interventional cardiology.
Front Neurol 2017;8:387.
50. Majidi S, Sein J, Watanabe M, Hassan AE, Van de Moortele PF, Suri MF, et al. Intracranial-derived atherosclerosis assessment: an in vitro comparison between virtual histology by intravascular ultrasonography, 7T MRI, and histopathologic findings.
AJNR Am J Neuroradiol 2013;34:2259-2264.
51. Debette S, Kamatani Y, Metso TM, Kloss M, Chauhan G, Engelter ST, et al. Common variation in PHACTR1 is associated with susceptibility to cervical artery dissection.
Nat Genet 2015;47:78-83.
52. Chen SP, Fuh JL, Wang SJ, Tsai SJ, Hong CJ, Yang AC. Brainderived neurotrophic factor gene Val66Met polymorphism modulates reversible cerebral vasoconstriction syndromes.
PLoS One 2011;6:e18024.
53. Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome-wide association study identifies RNF213 as the first moyamoya disease gene.
J Hum Genet 2011;56:34-40.
54. Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development.
PLoS One 2011;6:e22542.
55. Wu Z, Jiang H, Zhang L, Xu X, Zhang X, Kang Z, et al. Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population.
PLoS One 2012;7:e48179.
56. Cecchi AC, Guo D, Ren Z, Flynn K, Santos-Cortez RL, Leal SM, et al. RNF213 rare variants in an ethnically diverse population with moyamoya disease.
Stroke 2014;45:3200-3207.
57. Ma J, Liu Y, Ma L, Huang S, Li H, You C. RNF213 polymorphism and moyamoya disease: a systematic review and meta-analysis.
Neurol India 2013;61:35-39.
58. Gallai V, Caso V, Paciaroni M, Cardaioli G, Arning E, Bottiglieri T, et al. Mild hyperhomocyst(e)inemia: a possible risk factor for cervical artery dissection.
Stroke 2001;32:714-718.
59. Pezzini A, Del Zotto E, Archetti S, Negrini R, Bani P, Albertini A, et al. Plasma homocysteine concentration, C677T MTHFR genotype, and 844ins68bp CBS genotype in young adults with spontaneous cervical artery dissection and atherothrombotic stroke.
Stroke 2002;33:664-669.
60. Zhu Z, Tang W, Ge L, Han X, Dong Q. The value of plasma fibrillin-1 level in patients with spontaneous cerebral artery dissection.
Neurology 2018;90:e732-e737.
61. Bang OY, Chung JW, Kim SJ, Oh MJ, Kim SY, Cho YH, et al. Caveolin-1, ring finger protein 213, and endothelial function in moyamoya disease.
Int J Stroke 2016;11:999-1008.
62. Ahn SH, Lee J, Kim YJ, Kwon SU, Lee D, Jung SC, et al. Isolated MCA disease in patients without significant atherosclerotic risk factors: a high-resolution magnetic resonance imaging study.
Stroke 2015;46:697-703.
63. Kim YJ, Lee JK, Ahn SH, Kim BJ, Kang DW, Kim JS, et al. Nonatheroscleotic isolated middle cerebral artery disease may be early manifestation of moyamoya disease.
Stroke 2016;47:2229-2235.
64. Park MS, Cha J, Chung JW, Seo WK, Kim GM, Bang OY. Arterial dissection as a cause of intracranial stenosis in East Asians.
J Am Coll Cardiol 2017;70:2205-2206.
65. Kuriyama S, Kusaka Y, Fujimura M, Wakai K, Tamakoshi A, Hashimoto S, et al. Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey.
Stroke 2008;39:42-47.
66. Miao W, Zhao PL, Zhang YS, Liu HY, Chang Y, Ma J, et al. Epidemiological and clinical features of moyamoya disease in Nanjing, China.
Clin Neurol Neurosurg 2010;112:199-203.
67. Chen PC, Yang SH, Chien KL, Tsai IJ, Kuo MF. Epidemiology of moyamoya disease in Taiwan: a nationwide populationbased study.
Stroke 2014;45:1258-1263.
68. Kim T, Lee H, Bang JS, Kwon OK, Hwang G, Oh CW. Epidemiology of moyamoya disease in Korea: based on National Health Insurance Service Data.
J Korean Neurosurg Soc 2015;57:390-395.
69. Jung KH, Lee SH, Kim BJ, Yu KH, Hong KS, Lee BC, et al. Secular trends in ischemic stroke characteristics in a rapidly developed country: results from the Korean Stroke Registry Study (secular trends in Korean stroke).
Circ Cardiovasc Qual Outcomes 2012;5:327-334.
70. Kimura H, Takao M, Suzuki N, Kanemaru K, Mihara B, Murayama S. Pathologic study of intracranial large artery atherosclerosis in 7260 autopsy cases.
J Stroke Cerebrovasc Dis 2017;26:2821-2827.
71. Chen SP, Fuh JL, Wang SJ. Reversible cerebral vasoconstriction syndrome: an under-recognized clinical emergency.
Ther Adv Neurol Disord 2010;3:161-171.
72. Chaturvedi S, Turan TN, Lynn MJ, Kasner SE, Romano J, Cotsonis G, et al. Risk factor status and vascular events in patients with symptomatic intracranial stenosis.
Neurology 2007;69:2063-2068.
75. Toyoda K, Koga M, Hayakawa M, Yamagami H. Acute reperfusion therapy and stroke care in Asia after successful endovascular trials.
Stroke 2015;46:1474-1481.
77. Natarajan SK, Karmon Y, Tawk RG, Hauck EF, Hopkins LN, Siddiqui AH, et al. Endovascular treatment of patients with intracranial stenosis with moyamoya-type collaterals.
J Neurointerv Surg 2011;3:369-374.
78. Drazin D, Calayag M, Gifford E, Dalfino J, Yamamoto J, Boulos AS. Endovascular treatment for moyamoya disease in a Caucasian twin with angioplasty and Wingspan stent.
Clin Neurol Neurosurg 2009;111:913-917.
79. Khan N, Dodd R, Marks MP, Bell-Stephens T, Vavao J, Steinberg GK. Failure of primary percutaneous angioplasty and stenting in the prevention of ischemia in moyamoya angiopathy.
Cerebrovasc Dis 2011;31:147-153.
80. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association.
Stroke 2011;42:227-276.
81. Singhal AB, Topcuoglu MA. Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome.
Neurology 2017;88:228-236.
82. Mandell DM, Matouk CC, Farb RI, Krings T, Agid R, terBrugge K, et al. Vessel wall MRI to differentiate between reversible cerebral vasoconstriction syndrome and central nervous system vasculitis: preliminary results.
Stroke 2012;43:860-862.
83. Turk AS, Levy EI, Albuquerque FC, Pride GL Jr, Woo H, Welch BG, et al. Influence of patient age and stenosis location on wingspan in-stent restenosis.
AJNR Am J Neuroradiol 2008;29:23-27.
84. Miyawaki S, Imai H, Shimizu M, Yagi S, Ono H, Mukasa A, et al. Genetic variant RNF213 c.14576G>A in various phenotypes of intracranial major artery stenosis/occlusion.
Stroke 2013;44:2894-2897.
85. Bang OY, Chung JW, Cha J, Lee MJ, Yeon JY, Ki CS, et al. A polymorphism in RNF213 is a susceptibility gene for intracranial atherosclerosis.
PLoS One 2016;11:e0156607.
86. Fujimura M, Sonobe S, Nishijima Y, Niizuma K, Sakata H, Kure S, et al. Genetics and biomarkers of moyamoya disease: significance of RNF213 as a susceptibility gene.
J Stroke 2014;16:65-72.